Accueil   Diary - News   All news VALBIOTIS obtains the European patent for VALEDIA®

VALBIOTIS obtains the European patent for VALEDIA®

VALBIOTIS a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, announces
the obtention of the European patent for TOTUM-631.

 

This patent directly covers the active substance of VALEDIA® for use in 38 European countries on the prediabetes and metabolic diseases market, including type 2 diabetes and NAFLD. After obtaining the US patent in 2018, VALBIOTIS’ industrial property for VALEDIA® is now protected on its two main global markets (Europe and the United States). These markets have similar-sized prediabetic populations, each of which exceeds 80 million people2,3.

 

 

Read the press release

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree